Results 231 to 240 of about 106,090 (294)

OSA Initiates Histone Lactylation That Drives PDE4B/FUS/AGT Axis to Pulmonary Hypertension

open access: yesCell Proliferation, EarlyView.
This study illustrates how chronic intermittent hypoxia (CIH) in obstructive sleep apnea (OSA) leads to hypertension via increased oxidative stress and mitochondrial dysfunction in pulmonary artery smooth muscle cells (PASMCs), causing glycolytic dysregulation. Lactate accumulation enhances histone lactylation, upregulating phosphodiesterase 4B (PDE4B),
Li Yang   +12 more
wiley   +1 more source

Progression of albumin/creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR) over 24 years in people with type 2 diabetes. Drivers, potential protectors and associated mortality

open access: yesDiabetic Medicine, EarlyView.
Abstract Introduction The pathophysiology of chronic kidney disease (CKD) and type 2 diabetes (T2D) is multifactorial and associated with a plethora of underlying conditions and complications. Their link is reciprocal and understanding its nature, particularly over time, could improve the health of many.
Andreas Matheou   +13 more
wiley   +1 more source

Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young‐onset type‐2 diabetes in Hong Kong

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Those with young‐onset type‐2 diabetes (YOD), diagnosed before age of 40 years, experience heightened risk of complications. The economic burden extends beyond medical costs, impacting work productivity. Materials and Methods Chinese patients with YOD were recruited between June 2023 and April 2024 in the Precision Medicine to redefine ...
Juliana N. M. Lui   +14 more
wiley   +1 more source

Algorithms in Allergy: Hereditary Angioedema

open access: yes
Allergy, EarlyView.
Konrad Bork   +3 more
wiley   +1 more source

Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Clinical guidelines recommend sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for individuals with type 2 diabetes mellitus (T2DM) and established or high risk of cardiorenal disease. This study examined real‐world SGLT2i use patterns among older adults with T2DM in British Columbia, Canada.
Hanin Harbi   +10 more
wiley   +1 more source

Association between glucagon‐like peptide‐1 receptor agonists and risk of dementia in older adults with type 2 diabetes: A target trial emulation

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim Type 2 diabetes (T2D) is associated with increased dementia risk, but comparative data across newer glucose‐lowering therapies remain limited. We examined whether the initiation of GLP‐1 receptor agonists (GLP‐1 RAs) was associated with incident dementia compared with DPP4 inhibitors (DPP4is) and SGLT2 inhibitors (SGLT2is) in older adults ...
Ting Zhou   +9 more
wiley   +1 more source

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani   +5 more
wiley   +1 more source

Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double‐blind, multicentre, therapeutic confirmatory phase 3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim This study evaluated the efficacy and safety of empagliflozin 10 and 25 mg compared to placebo as add‐on treatment for people with type 2 diabetes mellitus (T2DM) uncontrolled after ≥8 weeks of treatment with metformin and sitagliptin. Materials and Methods A randomised, double‐blind, multicentre, therapeutic confirmatory, phase 3 clinical
Seung‐Hwan Lee   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy